Skip to main content

01.09.2009 | Focussed Research Review | Ausgabe 9/2009

Cancer Immunology, Immunotherapy 9/2009

The European searchable tumour line database

Cancer Immunology, Immunotherapy > Ausgabe 9/2009
James Robinson, Chrissy h. Roberts, I. Anthony Dodi, J. Alejandro Madrigal, Graham Pawelec, Lilly Wedel, Steven G. E. Marsh
Wichtige Hinweise
This paper is a focussed research review from the meeting which took place on the 28th–29th May 2008 in Nottingham, UK, celebrating the contribution of Prof. I.A. “Tony” Dodi (29.1.2008) to the EU project “Network for the identification and validation of antigens and biomarkers in cancer and their application in clinical tumour immunology (ENACT).”


The European Searchable Tumour line Database (ESTDAB) (http://​www.​ebi.​ac.​uk/​ipd/​estdab) is a freely available and fully searchable database of melanoma-derived cell lines, which have been characterised for over 250 immunologically relevant markers by a consortium of European scientists. The database is linked to a cell bank, which can provide melanoma cell lines to non-profit investigators for a nominal handling charge. All cells are fully HLA typed at the genomic and surface expression levels. The expression of a number of surface antigens, apoptotic markers, tumour-associated antigens and extracellular matrix proteins has also been determined. Cytokine secretion has been tested and polymorphisms in cytokine genes have been identified. Glycans at the cell surface were identified and glycosyltransferase activity quantified. Cell lines with a particular constellation of these parameters can be sought online via the ESTDAB interface, which is included as part of the Immuno-Polymorphism Database (IPD) section of the European Bioinformatics Institute’s (EBI) website.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der Fachzeitschriften, inklusive eines Print-Abos.

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2009

Cancer Immunology, Immunotherapy 9/2009Zur Ausgabe

Acknowledgement to Reviewers


  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.